Elegen

What Elegen does

Elegen is a Menlo Park-based biotechnology company founded in 2017 that has built a cell-free DNA synthesis platform intended to replace traditional plasmid-based cloning in synthetic biology workflows. Its flagship GEN II Cell-Free DNA Production Platform combines a directed split-pool microfluidic oligonucleotide synthesizer (the world's first, per company claims) with proprietary cell-free cloning technology that eliminates E. coli-based fermentation, plus an AI-driven production system that converts customer sequences into automated workcell protocols. The platform underpins three ENFINIA-branded product lines: Linear DNA (300 bp to 7 kb, 6–8 business-day turnaround), IVT Ready DNA (mRNA templates with poly(A) tails up to 5.5 kb), and Plasmid DNA (clonal genes up to 15 kb), all NGS-verified at a 1:70,000 bp error rate.

The company operates a hybrid go-to-market model: a self-serve e-commerce portal (ecommerce.elegen.com) serves academic and SMB customers with pay-as-you-go per-base-pair pricing (now $0.07/bp for standard complexity), while an enterprise field-sales motion engages pharmaceutical and CDMO partners for clinical manufacturing supply agreements, exemplified by a multi-year collaboration and licensing deal with GSK and a distribution partnership with IDT. Customer segments are organized horizontally across mRNA vaccine developers, cell and gene therapy companies, protein expression researchers, and synthetic biology firms, with named logos spanning GeneFrontier, Asimov, BASE mRNA Facility, Vernal Biosciences, and universities including UT Austin and CU Anschutz.

Elegen is venture-backed (cumulative ~$35M including a May 2024 Series B led by Triatomic Capital with strategic investment from GSK) and remains privately held under founder-CEO Matthew Hill. Recognition includes consecutive Fast Company Most Innovative Companies (2024, 2025), an R&D 100 Award, and Top 25 Biotech Companies of 2024 from The Healthcare Technology Report. The business is in a commercial scaling phase, with three product launches across 2025 and a disruptive ~50% price cut in January 2026 explicitly aimed at expanding share against incumbent DNA synthesis suppliers.

Name

Elegen

Legal name

Elegen Corp

Website

https://www.elegenbio.com/

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Elegen is a Menlo Park cell-free DNA synthesis company serving biotech, pharma, and academic researchers with NGS-verified ENFINIA Linear, IVT Ready, and Plasmid DNA products built on its patented microfluidic and cell-free cloning platform.

Ownership category

akta.pro rank

Product category

Synthetic DNA Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Cell-free DNA synthesis
• Synthetic biology tools
• Gene synthesis platform
• Microfluidic oligonucleotide synthesis
• DNA manufacturing services

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. ENFINIA DNA Product Sales: One-time sale of synthetic DNA products (Linear DNA, IVT Ready DNA, Plasmid DNA) with per-base-pair pricing. Revenue generated from synthesis fees based on sequence length and complexity.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Core offering

Elegen manufactures and sells NGS-verified synthetic DNA products through its proprietary cell-free GEN II production platform, eliminating the need for E. coli-based cloning. The ENFINIA product line includes Linear DNA (up to 7 kb, 6-8 day turnaround), IVT Ready DNA (with poly(A) tails for mRNA production), and Plasmid DNA (up to 15 kb), priced per base pair and sold directly to biotech, pharmaceutical, CDMO, and academic customers.

Product overview

Elegen offers a portfolio of cell-free DNA synthesis products built on the GEN II platform. The core ENFINIA product line includes three DNA formats: ENFINIA Linear DNA (sequences 300 bp to 7 kb, 6-8 day turnaround), ENFINIA IVT Ready DNA (mRNA templates with poly(A) tails up to 5.5 kb, 10-day turnaround), and ENFINIA Plasmid DNA (cloned sequences up to 15 kb, 10-day turnaround). All products leverage the GEN II platform's microfluidic oligonucleotide synthesis, AI-driven protocols, and proprietary cell-free cloning technology to deliver NGS-verified, high-accuracy DNA without bacterial fermentation.

Differentiator

Problem solved

Functional benefit

Brands

• ENFINIA DNA: Cell-free synthetic DNA product line including Linear DNA, IVT Ready DNA, and Plasmid DNA products
• GEN II Platform
• ENFINIA Linear DNA
• ENFINIA IVT Ready DNA
• ENFINIA Plasmid DNA

Products and services

• ENFINIA Linear DNA Cell-free linear DNA synthesis producing NGS-verified sequences from 300 bp to 7 kb with 99.999% per base accuracy (1:70,000 bp error rate), shipped in 6-8 business days without cloning required. Designed for biotech, pharmaceutical, and academic researchers needing rapid access to high-quality gene fragments.
• ENFINIA IVT Ready DNA Cell-free linear DNA templates with encoded poly(A) tails (70-130 adenosines) up to 5.5 kb for mRNA production via in vitro transcription. Shipped in 10 business days as reaction-ready constructs without downstream processing. Targeted at mRNA vaccine and therapeutic developers.
• ENFINIA Plasmid DNA Clonal gene synthesis service producing plasmid DNA up to 15 kb in standard or custom plasmid backbones, with high-complexity sequence support, NGS-verified and shipped in 10 business days. Targeted at advanced cell therapy, gene therapy, and synthetic biology applications.
• GEN II Cell-Free DNA Production Platform Automated manufacturing platform combining directed split-pool microfluidic oligonucleotide synthesis with AI-driven cell-free cloning technology for low-cost, high-diversity gene synthesis without bacterial fermentation. Enables approximately 50% price reduction on ENFINIA DNA products.

Quantifiable outcome

• 50% price reduction
• +5 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• Nutcracker TherapeuticscoreStrategic or Co-development Partner · 11 July 2025Pilot program to demonstrate the industry's first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). Combines Elegen's cell-free DNA synthesis with Nutcracker Therapeutics' RNA manufacturing capabilities.
• Integrated DNA Technologies (IDT)coreStrategic or Co-development Partner · 31 March 2025Strategic partnership marking launch of early access program offering rapid, long, clonal gene synthesis and high-complexity genes up to 15 kb. Combines Elegen's cell-free DNA manufacturing technology with IDT's distribution and market reach.
• GSKcoreStrategic or Co-development Partner · 14 May 2024GSK entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK's vaccines and medicines. GSK also participated in Elegen's $35M Series B funding round as a strategic investor. The collaboration leverages Elegen's ability to produce NGS-verified linear DNA up to 7 kb with error rates as low as 1:70,000 bp.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Twist Bioscience: Twist Bioscience is a leading DNA synthesis company offering gene fragments, genes, oligo pools, and DNA data storage on a silicon platform. Directly competes with Elegen in synthetic DNA for synthetic biology, antibody discovery, and next-generation sequencing workflows, with overlapping customers in pharma and academic research.
• GenScript: GenScript is a global biotechnology company offering gene synthesis, plasmid services, protein production, and cell therapy services. Directly competes with Elegen in gene synthesis and plasmid DNA offerings, serving similar biopharma and academic customers.
• Integrated DNA Technologies (IDT): IDT is a major supplier of custom oligonucleotides, genes, and synthetic biology products, and is now both an Elegen distribution partner and a competitor in gene synthesis. Directly comparable in product categories including custom DNA oligos, gene fragments, and related molecular biology reagents.
• DNA Script: DNA Script is a developer of enzymatic DNA synthesis (EDS) technology using a benchtop printer to synthesize oligonucleotides in-house. Competes with Elegen in the synthetic DNA market with a distinct enzymatic approach versus Elegen's cell-free microfluidic platform.

Emerging players

• Ansa Bio: Ansa Bio is an emerging player in enzymatic DNA synthesis focused on producing long, high-quality DNA for synthetic biology and therapeutic applications. Comparable to Elegen as a next-generation DNA synthesis platform pursuing differentiation via novel chemistry.
• Codex DNA: Codex DNA (formerly Synthetic Genomics) develops synthetic biology solutions including DNA synthesis and BioXp benchtop instruments for automated genome-scale engineering. Comparable to Elegen as a synthetic biology tools provider focused on accelerating DNA-based research workflows.
• Synbio Technologies: Synbio Technologies provides gene synthesis, DNA libraries, protein expression, and related services for synthetic biology applications. Comparable to Elegen as a gene synthesis service provider focused on complex and long DNA constructs.
• Camena Bioscience: Camena Bioscience is an emerging synthetic biology company developing high-fidelity DNA synthesis technology for gene and genome synthesis applications. Comparable to Elegen as a next-generation DNA synthesis platform pursuing accuracy and complexity differentiation.

Broad incumbents

• Eurofins Genomics: Eurofins Genomics is a global genomics services provider offering gene synthesis, DNA sequencing, oligonucleotides, and bioinformatics. Comparable to Elegen in gene synthesis and oligo services, with broader portfolio and global scale as an incumbent.
• Thermo Fisher Scientific (GeneArt): Thermo Fisher Scientific offers gene synthesis and synthetic biology services through its GeneArt brand, serving pharma, biotech, and academic customers. Comparable to Elegen as a gene synthesis provider, with substantially greater scale, distribution, and a broader life sciences portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/elegenbio
• LinkedInlinkedin.com/company/elegenbio
• YouTubeyoutube.com/c/ElegenBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elegen